Infantile hemangioma
Conditions
Interventions
oral propranolol group:oral propranolol alone
combination group:combination of oral propranolol and topical timolol
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients of infantile hemangioma that were diagnosed according to the criteria of the International Society for the Study of Vascular Anomalies, younger than 1 year old; 2. no previous treatment with other medications; and 3. agreement to the participation and signed the informed consent provided by patients guardians. ;Inclusion criteria: 1. Patients of infantile hemangioma that were diagnosed according to the criteria of the International Society for the Study of Vascular Anomalies, younger than 1 year old; 2. no previous treatment with other medications; and 3. agreement to the participation and signed the informed consent provided by patients guardians. ;Inclusion criteria: 1. Patients of infantile hemangioma that were diagnosed according to the criteria of the International Society for the Study of Vascular Anomalies, younger than 1 year old; 2. no previous treatment with other medications; and 3. agreement to the participation and signed the informed consent provided by patients guardians. ;Inclusion criteria: 1. Patients of infantile hemangioma that were diagnosed according to the criteria of the International Society for the Study of Vascular Anomalies, younger than 1 year old; 2. no previous treatment with other medications; and 3. agreement to the participation and signed the informed consent provided by patients guardians. ;Inclusion criteria: 1. Patients of infantile hemangioma that were diagnosed according to the criteria of the International Society for the Study of Vascular Anomalies, younger than 1 year old; 2. no previous treatment with other medications; and 3. agreement to the participation and signed the informed consent provided by patients guardians.
Exclusion criteria
Exclusion criteria: 1. patients who had a history of allergies to ß-adrenergic receptor antagonist and 2. had any contraindications or complications (e.g. ulceration, local infection, bronchial asthma); 3. congenital hemangioma.;Exclusion criteria: 1. patients who had a history of allergies to ß-adrenergic receptor antagonist and 2. had any contraindications or complications (e.g. ulceration, local infection, bronchial asthma); 3. congenital hemangioma.;Exclusion criteria: 1. patients who had a history of allergies to ß-adrenergic receptor antagonist and 2. had any contraindications or complications (e.g. ulceration, local infection, bronchial asthma); 3. congenital hemangioma.;Exclusion criteria: 1. patients who had a history of allergies to ß-adrenergic receptor antagonist and 2. had any contraindications or complications (e.g. ulceration, local infection, bronchial asthma); 3. congenital hemangioma.;Exclusion criteria: 1. patients who had a history of allergies to ß-adrenergic receptor antagonist and 2. had any contraindications or complications (e.g. ulceration, local infection, bronchial asthma); 3. congenital hemangioma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS;Spectral Doppler Ultrasound; | — |
Countries
China
Contacts
Public ContactLi Wei;Li Wei;Li Wei;Li Wei;Li Wei ;;;;
Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine;Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine;Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine;Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine;Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed